首页> 外文期刊>Expert opinion on biological therapy >Vaccines against myasthenia gravis.
【24h】

Vaccines against myasthenia gravis.

机译:预防重症肌无力的疫苗。

获取原文
获取原文并翻译 | 示例
           

摘要

Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies to nicotinic acetylcholine receptor (AChR) interfering with the neuromuscular transmission. Experimental autoimmune MG serves as an excellent animal model to study possible therapeutic modalities for MG. This review will focus on the different ways to turn off the autoimmune response to AChR, which results in suppression of myasthenia. This paper will describe the use of fragments or peptides derived from the AChR, antigen-presenting cells and anti-T cell receptor antibodies, and will discuss the underlying mechanisms of action. Finally, the authors propose new promising therapeutic prospects, including treatment based on the modulation of regulatory T cells, which have recently been found to be functionally defective in MG patients.
机译:重症肌无力(MG)是一种烟碱乙酰胆碱受体(AChR)抗体介导的干扰神经肌肉传递的自身免疫性疾病。实验性自身免疫性MG是研究MG可能治疗方式的出色动物模型。这篇综述将集中在关闭对AChR的自身免疫反应的不同方法上,这导致肌无力的抑制。本文将描述衍生自AChR,抗原呈递细胞和抗T细胞受体抗体的片段或肽的用途,并讨论其潜在的作用机理。最后,作者们提出了新的有前途的治疗前景,包括基于调节性T细胞调节的治疗方法,最近发现这在MG患者中是功能缺陷的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号